Guinea-Bissau Halts US-Backed Hepatitis B Vaccine Trial

Nov 6 · Trial aimed to compare infant vaccination timing Updated 17:17

Al Jazeera reported that the trial aimed to compare health outcomes between infants vaccinated at birth and those vaccinated six weeks later. Christine Stabell Benn and Peter Aaby argued they were studying whether the vaccine's prevention of disease comes at a 'prohibitive price' such as increased mortality. Researchers described the trial's failure to secure government approval as a setback for African science.

The researchers' framing of the trial as a 'setback for African science' attempts to shift the narrative from an ethical breach to a struggle for scientific autonomy [1]. This claim contrasts with the established pattern of the project bypassing local health authorities and utilizing a vulnerable population for a study that would be prohibited in the researchers' home country.

Al Jazeera provides the researchers' specific justification—that the vaccine may come at a 'prohibitive price' of increased mortality [1]. However, by focusing on the researchers' defense and the general condemnation from the WHO, the report omits the critical link between the trial's funding and the political influence of Robert F. Kennedy Jr. previously uncovered by other outlets.

Nov 5 · University of Southern Denmark conducted trial funded by Trump administration Updated 00:38

The BBC reported that the University of Southern Denmark conducted the trial, which was funded by the Trump administration via the CDC. According to the BBC, the trial's funding coincided with Robert F. Kennedy Jr.'s efforts to change US vaccine recommendations. The BBC also reported that the Guinea-Bissau government had previously prohibited trials of this nature, and Guinea-Bissau's Health Minister criticized the trial, claiming he was not informed of its progress. Additionally, the BBC stated that health experts and critics questioned why the study was conducted in a poor country instead of Denmark.

The trial's lack of transparency is now a matter of official record. The claim by Guinea-Bissau's Health Minister that he was not informed of the project's progress suggests the researchers may have bypassed national health authorities entirely [1].

BBC adds a critical geographic dimension to the ethical debate by questioning why the study was conducted in a poor country instead of Denmark [1]. This reinforces the earlier concern that the project exploited a fragile state to test a hypothesis that would be too controversial to pursue in a developed nation.

The timing of the funding further complicates the researchers' claim of scientific independence. The fact that the trial's financial support coincided with efforts to change US vaccine recommendations suggests the project may have served a specific policy goal [1].

Readers should now watch for a response from the University of Southern Denmark regarding the Health Minister's claims of being bypassed and whether the Danish misconduct investigation will address the specific decision to move the trial to Guinea-Bissau.

Oct 24 · Peter Aaby and Christine Stabell Benn under investigation for scientific misconduct Updated 14:50

Peter Aaby, a lead researcher of the Bandim Health Project, and Christine Stabell Benn are under investigation for scientific misconduct in Denmark. The Bandim Health Project is the subject of claims by the non-profit Stand Up for Science, which states the project may be exploiting the fragile state and failed to improve local health infrastructure over five decades. A trial involving the project was halted in January due to concerns that it could expose newborns to lifelong hepatitis B infections, and the Africa CDC opposed the trial. Robert F. Kennedy Jr. attempted to fund the trial using $1.6 million in US taxpayer dollars via the CDC. Defector alleges that Kennedy bypassed review standards to award that grant to the Bandim Health Project researchers. Ars Technica reported that the CDC may have set aside an additional $1.6 million to proceed with the trial.

The investigation into scientific misconduct in Denmark and the allegation that review standards were bypassed to award grants shift the debate. The trial is no longer just a dispute over medical ethics, but a question of institutional integrity and political interference in public health funding.

Defector provided a critical link by alleging that the $1.6 million grant was awarded by bypassing standard review processes to align with a specific anti-vaccine agenda. The Guardian added a colonial dimension to the critique, reporting claims from Stand Up for Science that the project exploited a fragile state without improving local health infrastructure for five decades.

Ars Technica deepened the scrutiny of the researchers by reporting that the lead scientists are under investigation for scientific misconduct in their home country. This undermines the researchers' defense that the trial was a legitimate effort to challenge medical orthodoxy.

Readers should now watch whether the CDC confirms the existence of the additional $1.6 million set aside for the trial and whether the Danish misconduct investigation reveals specific data manipulation or ethical breaches.